62 results about "Visceral fat" patented technology

The invention provides a dietary fiber anti-obesity and internal fat-reducing composition and a preparation method and application thereof, and the dietary fiber anti-obesity and internal fat-reducing composition comprises the following components in percentage by mass: a metabolic regulation formula which comprises 0.8-1.2% of mulberry leaf extract, 0.3-0.5% of potato extract, 0.2-0.4% of gamma-aminobutyric acid microcapsules and 4.0-6.0% of isomaltooligosacharide; the water management formula comprises 0.5 to 1.0 percent of opuntia ficus-indica powder and 0.2 to 0.4 percent of fructus gardeniae powder; the auxiliary regulation formula comprises the following components in percentage by weight: 2.0 to 4.0 percent of fructo-oligosaccharide, 0.05 to 0.15 percent of sucralose, 0.10 to 0.30 percent of xanthan gum and 0.05 to 0.15 percent of sodium citrate; and the nutrition fortification formula comprises 0.1-0.3% of taurine and 0.5-1.0% of a compound nutrition fortifier, and the compound nutrition fortifier contains vitamin B6 / B12, magnesium, iron and zinc. By constructing a fiber barrier-enzymolysis network-targeted metabolism three-in-one system, accurate reduction and control of visceral fat are achieved, fat oxidation combustion can be promoted, fat decomposition can be accelerated, fat accumulation can be reduced, and the method can be used for preparation of liquid beverages, preparation of powdery electuary and preparation of far infrared bagged powder solid beverages and has good application prospects. And the application scenarios are greatly increased.

The invention provides isolated Ackermania muciniphila, a composition containing the same and application of the Ackermania muciniphila in preventing re-fatting. According to the present invention, the Akkermansia muciniphila has characteristics of high automatic aggregation ability and strong surface hydrophobicity, can effectively adhere to the intestinal epithelial cells, can prolong the intestinal retention time, and can improve the treatment effect. The strain adapts to the intestinal environment and is high in stability. The Akkermansia muciniphila disclosed by the invention can be used for remarkably inhibiting body weight rebound (reducing body weight growth rate and fat accumulation) after drug withdrawal, improving blood sugar steady state (reducing postprandial blood sugar and fasting blood sugar) and reducing visceral fat accumulation, and the action is lasting and does not rebound. An efficient and safe microbial therapy solution is provided for maintaining the body weight and preventing an easily-fat object from developing obesity after obesity treatment.

The invention relates to the technical field of human body measurement, and discloses a body index evaluation device, method and system. The basic concept is that the body fat rate of a user is calculated according to the waistline and gender of the user; combining the body fat rate with the height and the weight to calculate one or more of fat mass, subcutaneous fat weight, visceral fat weight, visceral fat grade, segmental fat weight, skeletal muscle weight, segmental muscle weight, sarcopenia evaluation, moisture weight, mineral weight, protein weight and cell moisture of the user; the calculation method of the body fat rate is as follows: the male body fat rate is equal to 36.4-((110-waistline) * 0.6), and the female body fat rate is equal to 48-((110-waistline) * 0.6); and the value range of the waistline is 60 to 110 cm. According to the method, accurate data are obtained through calculation, the user can make preliminary body screening in multiple aspects with extremely low cost, and the method can be used for the category of obesity and sarcopenia so as to reduce the cost of screening related diseases by the government.

Lactobacillus fermentum is provided, where the Lactobacillus fermentum is Lactobacillus fermentum TCI757 and the Lactobacillus fermentum TCI757 was deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen under the accession number DSM 33914. A method of using Lactobacillus fermentum TCI757 of reducing fat and gaining muscle for a subject in need is also provided.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing visceral fat in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The invention discloses a limb multi-frequency rapid visceral fat measuring method and device, and the method comprises the steps: configuring a sensor which comprises four pairs of electrodes connected with limbs and a waistline sensor surrounding the waist; the visceral fat amount is calculated according to the measurement results of the electrodes of the limbs and the waistline sensor. Eight electrodes are matched with the waistline sensor for measurement, and the non-visceral fat amount of the human body can be calculated more accurately and quickly through multi-dimensional and multi-frequency complex impedance measurement.

The disclosure relates to studying physical properties of biological tissues, and for example, to a method and system for indirect estimation of the abdominal subcutaneous fat area and the abdominal visceral fat area. The technical result is reduced complexity and increased accuracy and speed of estimation of the abdominal subcutaneous fat area and the abdominal visceral fat area with portable devices. A method for determining the abdominal visceral fat area and the subcutaneous fat area in a body section in an abdominal region, comprises: using a device with ultra-wide band (UWB) radar applied to the body in the abdominal region, emitting radiation into the body and measuring parameters of reflected radiation; based on the reflected radiation measurement data obtained by the UWB radar, determining the abdominal subcutaneous fat area (ASFA) in the body section, corresponding to the measurement point; acquiring anthropometric data and bio-electrical impedance value of the body; based on the bio-electrical impedance data of the body and the anthropometric data, determining total fat area (TFA) in the body section in the abdominal region; calculating the abdominal visceral fat area (AVFA) in the body section from the determined total fat area and the abdominal subcutaneous fat area.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

Methods and uses are presented in which a therapeutically effective unit dose of dodecanedioic acid (DDDA or DC12) is administered for an extended period of time to improve a subject's lipid metabolism. Preferred dosage units comprise no more than 5% of the subject's standard daily caloric intake and improvements in metabolism are associated with weight loss and / or reduction of visceral fat.

The present invention relates to a microbiome composition of the fermentation culture supernatant of the halophilic Bacillus polyfermenticus KMU01 strain, which has anti-obesity effects. It has been confirmed that the fermentation culture supernatant of the strain deposited under accession number KCTC11751BP inhibits fat production and accumulation and reduces blood cholesterol levels. Therefore, the composition can be usefully used as a composition for preventing, treating, or ameliorating obesity; or as a composition for reducing body fat (visceral fat) or blood cholesterol.

The use of a postbiotic of Bifidobacterium brevis 207-1 (GDMCC No. 60962) or a composition containing the postbiotic in the preparation of a medicine or a food product. The medicine or food product is used for preventing and / or ameliorating diseases and / or symptoms related to fat gain in a subject. The diseases and / or symptoms are selected from weight gain, obesity, fatty liver, fat accumulation (e.g., visceral fat accumulation and subcutaneous fat accumulation), abnormal lipid metabolism, or any combination thereof. The medicine or food product can promote the fat breakdown and / or inhibit the fat absorption, maintain or reduce the body weight and / or BMI of the subject, increase the satiety of the subject, and reduce the food intake of the subject.

The present invention discloses a method for evaluating and managing body fat rate (BMI) and the effect of Zhanwei capsule based on intelligent monitoring, which relates to the technical field of body fat rate (BMI) and the effect of Zhanwei capsule, and includes the following steps: using intelligent monitoring technology to track the changes in the patient's body fat rate after using Zhanwei capsule in real time, dynamically record and continuously update relevant data, and build a comprehensive and systematic body fat rate data set to provide accurate data support for subsequent analysis and management. The present invention uses intelligent monitoring technology to collect body fat rate and visceral fat data, predicts the risk of hidden decrease in basal metabolic rate through support vector machine, and combines clustering algorithm to subdivide metabolic problem types, providing a basis for personalized intervention, making up for the deficiencies of existing technologies in dynamic monitoring and risk classification, significantly improving the accuracy of metabolic management, reducing the risk of obesity-related diseases, and optimizing patients' body fat rate and metabolic health.

The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.

The invention discloses an application of premna microphylla pectin in preparation of a product for preventing and improving diet-induced obesity. The premna pubescens pectin is prepared from premna pubescens leaves as a raw material through extraction, purification and other processes. According to the present invention, the research on the high fat diet induced obese mouse model finds that the body lipid metabolism is regulated by remodeling the intestinal flora structure, particularly reducing the ratio of the phylum firmicutes to the phylum bacteroides, and specifically enriching the beneficial flora such as Muribacaceae and the like by using the premna microphylla pectin; experimental results prove that the premna microphylla pectin can significantly inhibit pathological hypertrophy of adipocytes, reduce visceral fat accumulation, effectively control weight gain and improve dyslipidemia and liver fatty degeneration, and has good biological safety.

To provide an oral composition that can be used for anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or elevation suppression of blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation. 【Solution means】An oral composition containing gallocatechinol and hydroxycitric acid, wherein the mass ratio of gallocatechinol to hydroxycitric acid in the composition is gallocatechinol:hydroxycitric acid = 1:0.01 to 10. The oral composition preferably further contains isogallocatechinol.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The invention discloses a colorectal cancer postoperative risk assessment method, device and equipment and a storage medium, and relates to the technical field of colorectal cancer postoperative assessment, and the colorectal cancer postoperative risk assessment method comprises the following steps: based on a multi-head attention mechanism, segmenting a centrum horizontal CT image of a preoperative and postoperative third lumbar vertebra of a target object, and obtaining a centrum horizontal CT image of a second lumbar vertebra of the target object; obtaining a skeletal muscle area SMA, a visceral fat area VFA and a subcutaneous fat area SFA corresponding to preoperative and postoperative operations; respectively calculating a skeletal muscle index SMI and a visceral fat to subcutaneous fat ratio VSR according to SMA, VFA and SFA before and after the operation; according to the gender of the target object and the preoperative and postoperative SMI and VSR, judging whether the target object is sarcopenia and / or visceral fat obesity; and dividing risk levels according to preoperative and postoperative judgment results. Based on a multi-head attention mechanism, automatic accurate segmentation and risk assessment of the colorectal cancer postoperative body composition are realized, and the analysis efficiency and accuracy are remarkably improved.

The invention discloses a whole-body multi-end multi-frequency accurate visceral fat measuring method and device, and the method comprises the steps: configuring electrode pairs which comprise four groups of electrode pairs connected with four limbs and four groups of electrode pairs connected with the abdomen, and enabling sampling electrodes of the four groups of electrode pairs on the abdomen to be distributed at four points, the exciting electrodes of the four groups of electrode pairs on the abdomen are positioned outside the sampling electrodes; calculating the amount of non-visceral fat through the four groups of electrode pairs of the four limbs and the body weight; abdomen parameters are calculated through four groups of electrode pairs of the abdomen; and calculating the visceral fat mass according to the non-visceral fat mass and the abdominal parameters. According to the invention, the 16 electrodes are matched with the body weight sensor for measurement, and the non-visceral fat mass of the human body can be more accurately calculated through multi-dimensional and multi-frequency complex impedance measurement, so that the precision of visceral fat mass measurement is improved.

The present disclosure relates to treatment of Hypothalamic Obesity with Tesofensine alone or in combination with a beta-blocker. In particular the disclosure relates to treatments that lead to weight loss, loss of fat mass, in particular visceral fat, and to reduction of symptoms of pre-diabetes in patients suffering from Hypothalamic Obesity.

The invention discloses a functional nutritional feed for promoting muscle gaining and fat reducing of cattle and sheep and a preparation method thereof, and belongs to the technical field of enzyme engineering feed processing. The feed is suitable for the fattening stage of cattle and sheep, and can effectively improve the lean meat percentage, reduce visceral fat deposition and improve the meat quality through scientifically proportioned nutritional ingredients. The feed comprises the following main components: soybean meal, oligosaccharides, nattokinase, conjugated linoleic acid, a compound enzyme preparation, dry yeast powder and the like, and can promote the growth of bones and muscles and reduce the deposition of fat at the same time. Experimental results show that the nutritional feed has remarkable effects on improving daily gain, carcass weight, dressing percentage and lean meat percentage of cattle and sheep, is free of antibiotic and hormone residues, and is safe and green. By using the fattening feed, the problem of excessive fat accumulation caused by a traditional fattening method can be effectively solved, the breeding benefits are improved, and the requirements of the market for high-quality beef and mutton are met.

Provided is a novel preparation having an excellent lipolysis-promoting effect, an excellent visceral fat and body fat reducing effect, an excellent body weight reducing effect, and an excellent BMI improving effect. Another purpose of the present invention is to provide a novel preparation having an excellent insulin resistance improving effect, an excellent cholesterol value reducing effect, and the like. The present invention is an internal composition containing hirsutin B, which is used for at least one of lipolysis, fat burning, fat consumption assistance, BMI improvement, BMI reduction assistance, abdominal fat reduction, visceral fat reduction, body fat reduction, waist reduction, insulin resistance improvement, and LDL cholesterol value reduction. The internal composition of the present invention is preferably used for adults having a BMI of 23 kg / m < 2 > or more and less than 30 kg / m < 2 > and for adults having a visceral fat area of 100 cm < 2 > or more.

According to the easy-slimming fat-clearing essence health-care liquid disclosed by the invention, lotus leaf-hawthorn-semen pharbitidis synergistic compatibility is combined with a dynamic countercurrent extraction technology, so that the yield of total flavonoids is increased by 123%. The product is subjected to beta-cyclodextrin inclusion to eliminate unpleasant odor, the transdermal absorption rate can reach 68.7%, animal experiments prove that the product can significantly reduce the visceral fat index (reduced by 29.8%, Plt, 0.01) of a high-fat model rat, and the product is suitable for external application to improve the metabolic obesity problem.

A surgical device for reducing visceral fat in the abdominal cavity comprises an elongate shaft and an inflatable member. The inflatable member comprises a small-profile deflated configuration for being advanced into the abdominal cavity and a large-profile inflated configuration comprising a planar distal treatment surface for treating the visceral fat. The thermal fluid, preferably a gas, is circulated through the inflatable member at a temperature range sufficient to cause cryolipolysis to the fat cells but not damage non-target tissues. The inflatable member can have several chambers, reinforcing members, and ports to provide controlled flow patterns that maintain the shape of the inflatable member when inflated.

The invention relates to the field of environmental exposure omics and metabolic diseases, in particular to application of chlorpyrifos and paraquat in preparation of an abdominal obesity diagnosis product. The abdominal fat area, the A / S ratio, the liver fat content and other indexes measured through quantitative computed tomography (qCT) are combined, accurate recognition of abdominal obesity is achieved, the subjects with the normal body mass index (BMI) and visceral fat exceeding the standard can be effectively recognized, and the method has the advantages of being high in sensitivity, high in specificity and good in diagnosis foresight and has good application prospects. A new scheme is provided for early risk assessment and clinical screening of abdominal obesity, the significant correlation between the high exposure level of chlorpyrifos and paraquat and abdominal obesity supports the hypothesis that environmental endocrine disruptors promote obesity through metabolism interference, the urine concentration of chlorpyrifos and paraquat can be used as a novel biomarker, and the application prospect is broad. And a potential tool is provided for early screening of abdominal obesity.

A surgical device for reducing visceral fat in the abdominal cavity comprises an elongate shaft and an inflatable member. The inflatable member comprises a small-profile deflated configuration for being advanced into the abdominal cavity and a large-profile inflated configuration comprising a planar distal treatment surface for treating the visceral fat. The thermal fluid, preferably a gas, is circulated through the inflatable member at a temperature range sufficient to cause cryolipolysis to the fat cells but not damage non-target tissues. The inflatable member can have several chambers, reinforcing members, and ports to provide controlled flow patterns that maintain the shape of the inflatable member when inflated.

A fat mass derivation device includes at least one processor, in which the processor derives a fat mass distribution of a subject from a first radiation image and a second radiation image acquired by imaging the subject with radiation having different energy distributions, and derives a visceral fat mass distribution of the subject based on a shape of the fat mass distribution in a cross section orthogonal to a body axis of the subject.

The invention belongs to the technical field of biological medicines, and discloses a novel application of an epimedium aqueous extract, icariin and icaritin in improvement of senescence-related fat accumulation and redistribution. The invention constructs a nematode-mouse dual verification model: firstly, in a caenorhabditis elegans model, it is found that the active ingredients can significantly reduce fat droplet accumulation and triglyceride level in senescence nematode bodies, and especially under the concentration of 50 [mu] M, icariin can reduce the triglyceride content of 15-day-old senescence nematode to 37.58% of a control group. Furthermore, a naturally aged mouse is evaluated by utilizing a high-resolution Micro-CT (VivaCT 80) living body imaging technology, and three-dimensional reconstruction and quantitative analysis prove that the medicine can remarkably reduce the volume of visceral fat in the abdomen of the aged mouse, effectively improve the ratio of visceral fat to subcutaneous fat (VAT / SAT ratio) and reverse central obesity caused by aging. The raw materials are from natural plants, have no obvious toxic or side effect after long-term administration, can accurately improve fat space distribution of aging organisms, and have significant clinical application value.

The present application belongs to the technical field of artificial intelligence medical treatment, and provides a visceral fat prediction method and system based on language model enhancement and a medium, comprising: acquiring baseline physiological data and a diet plan; generating semantic vectors for features through a pre-trained language model, and fusing the semantic vectors with numerical data to generate semantic enhancement features; predicting a first prediction result of visceral fat change through a first prediction model; acquiring early physiological response data in the middle of intervention; generating a second prediction result through a second prediction model in combination with the early response data; and generating personalized intervention suggestions based on comparison of the second prediction result with a preset threshold. The present application introduces biomedical semantics of features and constructs a two-stage dynamic prediction architecture, solves the problems of low prediction accuracy and inability to utilize feature biomedical semantics, significantly improves prediction accuracy, and realizes closed-loop personalized intervention guidance.

The present invention provides isolated Akkermansia muciniphila, a composition containing the same, and its use in preventing weight regain. Akkermansia muciniphila ) has high autoaggregation ability and strong surface hydrophobicity, can effectively adhere to intestinal epithelial cells, prolong intestinal residence time, and improve therapeutic effects. This strain adapts to the intestinal environment and has high stability. The present invention's Akkermansia muciniphila ( Farmhouse mucinophila ) can significantly inhibit weight rebound after discontinuation (reducing weight gain and fat accumulation), improve blood sugar homeostasis (lowering postprandial and fasting blood sugar levels), and reduce visceral fat accumulation, with long-lasting effects. This provides a highly effective and safe microbial therapy solution for maintaining weight after obesity treatment and preventing obesity progression in individuals prone to obesity.